Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues     $ 50  
Operating expenses:        
Research and development $ 904 $ 2,644 4,045 $ 7,971
General and administrative 2,722 3,525 9,230 16,407
Total operating expenses 3,626 6,169 13,275 24,378
Operating loss (3,626) (6,169) (13,225) (24,378)
Other income (expense):        
Interest expense (52) (35) (112) (66)
Interest income 43 23 140 163
Loss on sale of debt securities   (98)   (98)
Gain on sale of intellectual property 1,000   1,000 0
Total other income 991 (110) 1,028 (1)
Net loss from continuing operations (2,635) (6,279) (12,197) (24,379)
Loss from discontinued operations (537) (1,015) (4,932) (34,598)
Net loss (3,172) (7,294) (17,129) (58,977)
Comprehensive loss:        
Consolidated net loss (3,172) (7,294) (17,129) (58,977)
Other comprehensive loss - unrealized loss on debt securities   134   180
Other comprehensive income - foreign currency adjustment   33   33
Comprehensive loss $ (3,172) $ (7,127) $ (17,129) $ (58,764)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.71) $ (9.53) $ (5.43) $ (46.00)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.71) (9.53) (5.43) (46.00)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.14) (1.54) (2.19) (65.28)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.14) (1.54) (2.19) (65.28)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.85) (11.07) (7.62) (111.28)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.85) $ (11.07) $ (7.62) $ (111.28)
Weighted-average common shares outstanding - basic 3,713 659 2,247 530
Weighted-average common shares outstanding - diluted 3,713 659 2,247 530